| Dr Salman Porbandarwalla, MD, MS | |
|
2150 Harrisburg Pike Ste 370, Lancaster, PA 17601-2644 | |
| (717) 399-8790 | |
| (717) 399-8790 |
| Full Name | Dr Salman Porbandarwalla |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 10 Years |
| Location | 2150 Harrisburg Pike Ste 370, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245490663 | NPI | - | NPPES |
| 1245490663 | Medicaid | WA | |
| 0293739 | Other | WA | L&I |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | MD451283 (Pennsylvania) | Primary |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.
While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.
Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.
AssistMed, Inc. today announced the release of a data transformation platform, Duet™, that enables healthcare professionals to dictate or handwrite medical information and receive it back securely as digital input for their healthcare information systems.
› Verified 3 days ago
| Entity Name | Conestoga Eye Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952780520 PECOS PAC ID: 1456669894 Enrollment ID: O20151005000084 |
News Archive
SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.
While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.
Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.
AssistMed, Inc. today announced the release of a data transformation platform, Duet™, that enables healthcare professionals to dictate or handwrite medical information and receive it back securely as digital input for their healthcare information systems.
› Verified 3 days ago
| Entity Name | Retina Associates Of Lancaster Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225744782 PECOS PAC ID: 2668846296 Enrollment ID: O20230323000028 |
News Archive
SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.
While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.
Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.
AssistMed, Inc. today announced the release of a data transformation platform, Duet™, that enables healthcare professionals to dictate or handwrite medical information and receive it back securely as digital input for their healthcare information systems.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Salman Porbandarwalla, MD, MS 2150 Harrisburg Pike Ste 370, Lancaster, PA 17601-2644 Ph: (717) 399-8790 | Dr Salman Porbandarwalla, MD, MS 2150 Harrisburg Pike Ste 370, Lancaster, PA 17601-2644 Ph: (717) 399-8790 |
News Archive
SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.
While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.
Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.
AssistMed, Inc. today announced the release of a data transformation platform, Duet™, that enables healthcare professionals to dictate or handwrite medical information and receive it back securely as digital input for their healthcare information systems.
› Verified 3 days ago
John William Sharp Jr., MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1254 Lititz Pike, Lancaster, PA 17601 Phone: 717-397-4724 Fax: 717-397-6687 | |
William M Spitler Iii, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2108 Harrisburg Pike, Ste 100, Lancaster, PA 17601 Phone: 717-544-3900 Fax: 717-544-3910 | |
Dr. Patrick T Tiedeken, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Noll Dr Ste 400, Lancaster, PA 17603 Phone: 717-417-8950 | |
Dr. Justin L Cappiello, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 324 N Duke St, Lancaster, PA 17603 Phone: 717-394-6808 Fax: 717-299-4133 | |
Adam Ryan Thode, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2115 Noll Dr, Lancaster, PA 17603 Phone: 717-393-7980 Fax: 717-509-5079 | |
Dina Y. Gewaily, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2150 Harrisburg Pike, Ste 370, Lancaster, PA 17601 Phone: 717-399-8790 Fax: 717-399-3279 | |
Pierre K Palandjian, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1254 Lititz Pike, Lancaster, PA 17601 Phone: 717-397-4724 Fax: 717-397-6687 |